221243-13-6

Basic information

• Product Name: 2-(1-METHOXY-2-(NAPHTHALEN-1-YL)ETHYLIDENE)MALONONITRILE
• Synonyms: 2-(1-METHOXY-2-(NAPHTHALEN-1-YL)ETHYLIDENE)MALONONITRILE
• CAS NO: 221243-13-6
• Molecular Formula: C₁₆H₁₂N₂O
• Molecular Weight: 248.27928
• Mol File: 221243-13-6.mol
• Article Data: 5

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 2-(1-METHOXY-2-(NAPHTHALEN-1-YL)ETHYLIDENE)MALONONITRILE(CAS DataBase Reference)
• NIST Chemistry Reference: 2-(1-METHOXY-2-(NAPHTHALEN-1-YL)ETHYLIDENE)MALONONITRILE(221243-13-6)
• EPA Substance Registry System: 2-(1-METHOXY-2-(NAPHTHALEN-1-YL)ETHYLIDENE)MALONONITRILE(221243-13-6)

Safety Data

• Hazardous Substances Data: 221243-13-6(Hazardous Substances Data)

Usage

Description

2-(1-METHOXY-2-(NAPHTHALEN-1-YL)ETHYLIDENE)MALONONITRILE is an organic compound that serves as a crucial intermediate in the synthesis of various pharmaceutical compounds. It is characterized by its unique chemical structure, which includes a methoxy group, a naphthalenyl group, and a malononitrile group. 2-(1-METHOXY-2-(NAPHTHALEN-1-YL)ETHYLIDENE)MALONONITRILE plays a significant role in the development of potent and specific inhibitors for targeted therapies.

Uses

Used in Pharmaceutical Industry:
2-(1-METHOXY-2-(NAPHTHALEN-1-YL)ETHYLIDENE)MALONONITRILE is used as an intermediate in the synthesis of 4-Amino-1-tert-butyl-3-(1’-naphthylmethyl)pyrazolo[3,4-d]pyrimidine (A603003), a highly potent and uniquely specific tyrosine kinase inhibitor. This inhibitor is designed to target a rationally engineered v-Src tyrosine kinase, which is a crucial protein in various cellular signaling pathways. By inhibiting this enzyme, A603003 can potentially disrupt the signaling pathways involved in cell proliferation, differentiation, and survival, making it a promising candidate for the development of targeted therapies against cancer and other diseases.
The application of 2-(1-METHOXY-2-(NAPHTHALEN-1-YL)ETHYLIDENE)MALONONITRILE in the pharmaceutical industry is primarily due to its ability to contribute to the development of highly specific and potent inhibitors. These inhibitors can be used to target specific proteins or enzymes involved in various diseases, leading to more effective and targeted treatments with fewer side effects. The compound's unique chemical structure allows it to be a valuable building block in the synthesis of such inhibitors, making it an essential component in the development of novel therapeutic agents.

Upstream product

• 77-78-1 dimethyl sulfate 
• 5121-00-6 naphthalen-1-yl-acetyl chloride 
• 86-87-3 naphth-1-yl acetic acid 

Downstream Products

• 221243-77-2 5-amino-1-tert-butyl-3-naphthalen-1-ylmethyl-1H-pyrazole-4-carbonitrile 
• 476371-69-4 3-naphthalen-1-ylmethyl-1H-pyrazolo[3,4-d]pyrimidin-4-ylamine 
• 476371-73-0 1-((2S,3R,4S,5R)-3,4-dibenzoyl-5-benzoylmethyltetrahydrofuran-2-yl)-3-naphthalen-1-ylmethyl-1H-pyrazolo[3,4-d]pyrimidin-4-ylamine 
• 221244-14-0 1-tert-butyl-3-(naphthalen-1-ylmethyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine 

Relevant articles and documents

Discovery of a potent protein kinase D inhibitor: insights in the binding mode of pyrazolo[3,4-d]pyrimidine analogues

In this study, we set out to rationally optimize PKD inhibitors based on the pyrazolo[3,4-d]pyrimidine scaffold. The lead compound for this study was 1-NM-PP1, which was previously found by us and others to inhibit PKD. In our screening we identified one compound (3-IN-PP1) displaying a 10-fold increase in potency over 1-NM-PP1, opening new possibilities for specific protein kinase inhibitors for kinases that show sensitivity towards pyrazolo[3,4-d]pyrimidine derived compounds. Interestingly the observed SAR was not in complete agreement with the commonly observed binding mode where the pyrazolo[3,4-d]pyrimidine compounds are bound in a similar fashion as PKD's natural ligand ATP. Therefore we suggest an alternate binding mode where the compounds are flipped 180 degrees. This possible alternate binding mode for pyrazolo[3,4-d]pyrimidine based compounds could pave the way for a new class of specific protein kinase inhibitors for kinases sensitive towards pyrazolo[3,4-d]pyrmidines.

COMPOSITIONS AND METHODS FOR TREATING TOXOPLASMOSIS. CRYPTOSPORIDIOSIS AND OTHER APICOMPLEXAN PROTOZOAN RELATED DISEASES

Compositions and methods for the treatment of toxoplasmosis-, caused by the infectious eukaryotic parasite Toxoplasma gondii (T, gondii) and for the treatment of ciyptosporidiosis, caused by the infectious eukaryotic parasites Cryptosporidium parvum (C parvuai) and Cnγtosporidium homimus (C. hominus) are described. In particular, the present disclosure is directed to compositions and methods for inhibiting either T. gondii calcium dependent protein kinases (TgCDPKs) or C. parvum and C. hominus calcium dependent protein kinases (CpDPKS) using pyrazolopyriinidine and/or imidazo[l,5-a]pyraziαe inhibitors, of the formula.(I), wherein the variables X. Y, Z, L. R1. and R3 are defined herein.

Generation of monospecific nanomolar tyrosine kinase inhibitors via a chemical genetic approach

Selective protein kinase inhibitors are highly sought after as tools for studying cellular signal transduction cascades, yet few have been discovered due to the highly conserved fold of kinase catalytic domains. Through a combination of small molecule syn